Supplementation with daily doses of 0.83 to 9.0 g resulted in beneficial changes in liver fat, plasma triglyceride and gamma-glutamyl-transferase (GGT) levels in patients with NAFLD while alanine aminotransferase (ALT) and aspartate aminotransferase (AST) remained unchanged [150]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.